BIOHEART-B(02185): IBERIS RDN system registered in Israel.

BIOHEART-B (02185) Announcement: Recently, the Iberis multi-pole renal artery radiofrequency ablation catheter system (Iberis RDN system) developed by the company's subsidiary, Shanghai Antong Medical Technology Co., Ltd. (Antong), has been registered in Israel. This registration is supported jointly by Bosch International Group Limited (Bosch) and Antong. Antong and Bosch have established a strategic partnership for the commercialization of the Iberis RDN system, with cooperation covering multiple regions including, but not limited to, EU countries, the Asia-Pacific region, and the Latin America (LATAM) region. As of the date of this announcement, the Iberis RDN system is the only renal denervation (RDN) product approved for use with the transradial artery (TRA) and transfemoral artery (TFA) routes globally. TRA makes RDN safer, more effective, and more cost-effective. The company's ultimate goal is to provide outpatient RDN procedures for patients worldwide. Antong obtained the CE mark for the Iberis RDN system in Europe in 2016.